donepezil has been researched along with Huntington Disease in 3 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| " We studied whether donepezil improves chorea, cognition, and quality of life (QoL) in HD." | 9.12 | Effect of donepezil on motor and cognitive function in Huntington disease. ( Bernard, BA; Cubo, E; Jaglin, JA; Leurgans, SE; Shannon, KM; Tracy, D; Wuu, J, 2006) |
| " We studied whether donepezil improves chorea, cognition, and quality of life (QoL) in HD." | 5.12 | Effect of donepezil on motor and cognitive function in Huntington disease. ( Bernard, BA; Cubo, E; Jaglin, JA; Leurgans, SE; Shannon, KM; Tracy, D; Wuu, J, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A | 1 |
| Bolognesi, ML | 1 |
| Minarini, A | 1 |
| Rosini, M | 1 |
| Tumiatti, V | 1 |
| Recanatini, M | 1 |
| Melchiorre, C | 1 |
| Cubo, E | 1 |
| Shannon, KM | 1 |
| Tracy, D | 1 |
| Jaglin, JA | 1 |
| Bernard, BA | 1 |
| Wuu, J | 1 |
| Leurgans, SE | 1 |
| Fernandez, HH | 1 |
| Friedman, JH | 1 |
| Grace, J | 1 |
| Beason-Hazen, S | 1 |
1 review available for donepezil and Huntington Disease
| Article | Year |
|---|---|
Multi-target-directed ligands to combat neurodegenerative diseases.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium | 2008 |
2 trials available for donepezil and Huntington Disease
| Article | Year |
|---|---|
Effect of donepezil on motor and cognitive function in Huntington disease.
Topics: Chorea; Cognition Disorders; Donepezil; Female; Humans; Huntington Disease; Indans; Male; Middle Age | 2006 |
Donepezil for Huntington's disease.
Topics: Adult; Aged; Cholinesterase Inhibitors; Donepezil; Female; Humans; Huntington Disease; Indans; Male; | 2000 |